Expression of DNA damage checkpoint protein Hus1 in epithelial ovarian tumors correlates with prognostic markers

International Journal of Gynecological Pathology

Volumn 27, Issue 1, 2008, Pages 24-32

  De La Torre, Javier ^a,b   Gil Moreno, Antonio ^b   García, Angel ^b   Rojo, Federico ^b   Xercavins, Jordi ^b   Salido, Eduardo ^a   Freire, Raimundo ^a  

^a HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

9 1 1 complex; Apoptosis; DNA damage checkpoint; Epithelial ovarian carcinoma; Hus1; Rad9

Indexed keywords

BIOLOGICAL MARKER; BIOTIN; CELL CYCLE PROTEIN; DNA POLYMERASE; EOSIN; HEMATOXYLIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN HUS1; PROTEIN P53; PROTEIN RAD9; STREPTAVIDIN; CYCLIN D1; HUS1B PROTEIN, HUMAN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYSTADENOMA; DNA DAMAGE; ENDOMETRIOID CARCINOMA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MITOSIS; NICK END LABELING; OVARY ADENOCARCINOMA; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; BIOSYNTHESIS; GENE EXPRESSION; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; NEOPLASM; OVARY TUMOR; PATHOLOGY; PHYSIOLOGY;

ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CELL CYCLE PROTEINS; CYCLIN D1; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; KAPLAN-MEIERS ESTIMATE; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 39349086205     PISSN: 02771691     EISSN: None     Source Type: Journal    
DOI: 10.1097/pgp.0b013e31812dfaef     Document Type: Article

References (24)

1. Gajewski W, Legare RD. Ovarian cancer. Surg Oncol Clin N Am 1998;7:317-33.
2. Ozols RF, Bookman MA, Connolly DC, et al. Focus on epithelial ovarian cancer. Cancer Cell 2004;5:19-24.
3. Rouse J, Jackson SP. Interfaces between the detection, signaling, and repair of DNA damage. Science 2002;297:547-51.
4. Melo J, Toczyski D. A unified view of the DNA-damage checkpoint. Curr Opin Cell Biol 2002;14:237-45.
5. Bartkova J, Horejsi Z, Koed K, et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005;434:864-70.
6. Gorgoulis VG, Vassiliou LV, Karakaidos P, et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 2005;434:907-13.
7. Kastan MB, Bartek J. Cell-cycle checkpoints and cancer. Nature 2004;432:316-23.
8. Parrilla-Castellar ER, Arlander SJ, Karnitz L. Dial 9-1-1 for DNA damage: the Rad9-Hus1-Rad1 (9-1-1) clamp complex. DNA Repair (Amst) 2004;3:1009-14.
9. Weiss RS, Matsuoka S, Elledge SJ, et al. Hus1 acts upstream of chk1 in a mammalian DNA damage response pathway. Curr Biol 2002;12:73-7.
10. Komatsu K, Miyashita T, Hang H, et al. Human homologue of S. pombe Rad9 interacts with BCL-2/BCL-xL and promotes apoptosis. Nat Cell Biol 2000;2:1-6.
11. Yin Y, Zhu A, Jin YJ, et al. Human RAD9 checkpoint control/proapoptotic protein can activate transcription of p21. Proc Natl Acad Sci U S A 2004;101:8864-9.
12. Cheng CK, Chow LW, Loo WT, et al. The cell cycle checkpoint gene Rad9 is a novel oncogene activated by 11q13 amplification and DNA methylation in breast cancer. Cancer Res 2005;65:8646-54.
13. Maniwa Y, Yoshimura M, Bermudez VP, et al. Accumulation of hRad9 protein in the nuclei of nonsmall cell lung carcinoma cells. Cancer 2005;103:126-32.
14. Hirai I, Sasaki T, Wang HG. Human hRad1 but not hRad9 protects hHus1 from ubiquitin-proteasomal degradation. Oncogene 2004;23:5124-30.
15. Soini Y, Paakko P, Lehto VP. Histopathological evaluation of apoptosis in cancer. Am J Pathol 1998;153:1041-53.
16. Selva DM, Tirado OM, Toran N, et al. Meiotic arrest and germ cell apoptosis in androgen-binding protein transgenic mice. Endocrinology 2000;141:1168-77.
17. Toueille M, El-Andaloussi N, Frouin I, et al. The human Rad9/Rad1/Hus1 damage sensor clamp interacts with DNA polymerase b and increases its DNA substrate utilisation efficiency: implications for DNA repair. Nucleic Acids Res 2004;32:3316-24.
18. Chan WY, Cheung KK, Schorge JO, et al. Bcl-2 and p53 protein expression, apoptosis, and p53 mutation in human epithelial ovarian cancers. Am J Pathol 2000;156:409-17.
19. Geisler JP, Geisler HE, Miller GA, et al. p53 and bcl-2 in epithelial ovarian carcinoma: their value as prognostic indicators at a median follow-up of 60 months. Gynecol Oncol 2000;77:278-82.
20. St Onge RP, Udell CM, Casselman R, et al. The human G2 checkpoint control protein hRAD9 is a nuclear phosphoprotein that forms complexes with hRAD1 and hHUS1. Mol Biol Cell 1999;10:1985-95.
21. Wang L, Hsu CL, Ni J, et al. Human checkpoint protein hRad9 functions as a negative coregulator to repress androgen receptor transactivation in prostate cancer cells. Mol Cell Biol 2004;24:2202-13.
22. Schaner ME, Ross DT, Ciaravino G, et al. Gene expression patterns in ovarian carcinomas. Mol Biol Cell 2003;14:4376-86.
23. Welsh JB, Zarrinkar PP, Sapinoso LM, et al. Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc Natl Acad Sci U S A 2001;98:1176-81.
24. Ejima Y, Yang L. Determination of the genotype of a panel of human tumor cell lines for the human homologues of yeast cell cycle checkpoint control genes: identification of cell lines carrying homoallelic missense base substitutions. Somat Cell Mol Genet 1999;25:41-8.